Home
overview

For the latest COVID-19 Travel restrictions and recommendations please click here

SAE Media Group’s 22nd Annual Conference
Pain Therapeutics
4 - 5 May, 2022 | London, UK
-------------------------------------------------------------------------
To register your interest or to get involved please contact:Join Europe’s leading Pain Therapeutics Conference, to explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.


The 22nd annual conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the latest advancements in the field, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore, policy experts will provide an essential regulatory perspective for this year’s agenda, providing an exciting and comprehensive insight into the pain therapeutics market.


New case studies and regulatory perspectives will bring together the challenges and successes of both pre-clinical and clinical development to equip you with the necessary knowledge to advance the pain therapeutic industry.
 

Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

  • Pain and Migraine
  • Inflammation
  • Chronic Pain
  • Neuropathic Pain
  • Analgesic pre-clinical development
  • Anaesthesia and Pain Management
  • CNS clinical trials
  • Ion Channel Pharmacology
  • Pharmacology Intelligence
  • Translational science
  • Drug development
  • Exploratory development

Algiax Pharmaceuticals Gmbh; Allergan; Asahi Kasei Pharma Corporation; AstraZeneca; AstraZeneca R&D Biopharmaceuticals; Cambridge Cognition Ltd.; Clexio Biosciences; Collegium Pharmaceuticals; Eli Lilly & Company; Eli Lilly and Company; Genentech; GlaxoSmithKline (GSK); Grunenthal Gmbh; Grünenthal GmbH; GSK; IPSEN; Ipsen Bioinnovation; Ipsen Innovation; Johns Hopkins University; Levicept Ltd; Lotus Clinical Research, LLC; LotusCR; McGill University; McGill University (Human Pain Genetics Lab); MD Biosciences; MD Biosciences Inc; Metys Pharmaceuticals; Metys Pharmaceuticals AG; Metys Pharmaceuticals Ltd; National Institute of Neurological Disorders and Stroke; National Institutes of Health; Navega Therapeutics; Neumentum; Neurana Pharmaceuticals; NINDS/NIH; Novaremed; Orion Pharma; Sygnature Discovery ; Taro Pharmaceutical Industries LTD.; TEVA Hungary; Teva Pharmaceuticals; THE ANN HAYES CONSULTANCY; The Johns Hopkins Hospital; Transpharmation Ltd; Vapogenix; Vifor Pharma Ltd;

Conference programme

8:30 Registration and Coffee

9:00 Chair's Opening Remarks

Richard Malamut

Richard Malamut, Chief Medical Officer, MedinCell,Inc
View Bio

9:10 “Pain is Pain – or is it?” – Perspectives on Chronic Pain

Arun Bhaskar

Arun Bhaskar, President, The British Pain Society
View Bio

  • Chronic pain results in major health and welfare expenditure, but its management is not well supported
  • The multifactorial biopsychosocial aspects of pain is often not acknowledged resulting in poor management
  • Pharmacological management are often targeting symptom control rather than treating the cause
  • Multimodal interdisciplinary management is needed but is delivered piece-meal
  • 9:50 Using transcriptomics to gain a deeper understanding of chronic pain diseases

    Candler Paige

    Candler Paige, Chief Executive Officer, Doloromics

  • Spatially characterizing the dorsal root ganglion (DRG)
  • Generating uniquely rich multi-omics datasets, which will combine spatial transcriptomics information, bulk RNA sequencing, and single nucleus split-sequencing
  • The benefits and importance of collaboration for developing novel therapeutics for chronic pain conditions
  • 10:30 Morning Coffee

    11:00 People suffering from Fibromyalgia: Challenges in clinical study setting before and during Covid-19 pandemic

    Domenico Merante

    Domenico Merante, Clinical Development Lead of Nephrology and Orphan Diseases, Vifor Pharma Ltd
    View Bio

  • An overview into how the covid-19 pandemic has affected patients with Fibromyalgia
  • Understanding the changes in treatments and the impact on the clinical setting
  • Challenges of patients suffering with fibromyalgia before the pandemic compared to during
  • How the treatment has improved in recent months, where are we now?
  • 11:40 Preventive medication for the treatment of migraine. The role of CGRP.

  • The role of CGRP in the body
  • CGRP and Migraine
  • Targeting CGRP to treat migraine
     
  • Michael J. Seminerio

    Michael J. Seminerio, Senior Global Scientific/Medical Lead Migraine Neuroscience, AbbVie Pharmaceuticals

    12:20 Networking Lunch

    13:30 Challenges in Analgesics development for Acute and Chronic Pain

  • New Mechanisms and NCEs for Analgesia - Where do we Stand?
  • Review of Current and Recent Developments for Acute and Chronic Pain
  • Opioid Replacement and Sparing Strategies
  • Impact of the US Opioid Crisis on Clinical Development Targets for Non-Opioid Analgesics
  • Review of Clinical Endpoints Related to Opioid-Sparing and Opioid Replacement in Clinical Trials - Relevance for Trial Designs and Results
  • Review of the Regulatory Environment
  • Updates Regarding Guidance Documents (Europe/US) and Impact on Labelling Targets for New Developments
  • Recent Outcomes of Approval Procedures and Possible Learnings
     

     

  • Ilona Steigerwald

    Ilona Steigerwald, Experienced Senior Executive and Chief Medical Officer, SVP,
    View Bio

    14:10 AOBiome’s drug development program for the treatment of Pruritus associated with Atopic Dermatitis

    Todd Krueger

    Todd Krueger, President and CEO, AOBiome
    View Bio

  • An introduction to Atopic Dermatitis and Pruritus
  • Discussion of mechanisms and pre-clinical development work
  • Review of clinical results and the challenges faced
  • The future outlook for this research
  • 14:50 Afternoon Tea

    15:20 The Abdominoplasty Acute Postoperative Pain Model: Insights from 8 Years of Clinical Trials

    Neil Singla

    Neil Singla, Chief Executive Officer, Lotus Clinical Research, LLC
    View Bio

  • Development history of abdominoplasty as a fast-recruiting, highly standardized soft tissue model (similar to bunionectomy in hard tissue)
  • Clinical characteristics of abdominoplasty as an experimental model
  • Best practices for design and conduct of abdominoplasty studies
  • Analysis of public data from industry studies performed to date
  • 16:00 The NIH HEAl Initiative/national Institute of neurological Disorders and Stroke's Early Phase Pain Investigation Clinical Network (EPPIC-Net): Year 2 Update

    Barbara Karp

    Barbara Karp, Program Director, EPPIC-Net, National Institutes Of Health

  • Part of the NIH Helping to End Addiction Long-term (HEAL) InitiativeSM , the Early Phase Pain Investigation Clinical Network (EPPIC-Net) provides complete phase 2 clinical trials for novel and repurposed pain therapeutics (including drugs and devices) selected through a rigorous application and review process. Trials can incorporate novel trial design, proof-of-concept testing, and biomarker validation and are provided at no cost to the applicant. the applicant retains intellectual property rights to their asset
  • EPPIC-Net’s clinical trial infrastructure includes a Clinical Coordinating Center, Data Coordinating Center, and 12 Specialized Clinical Centers (Hubs and Spokes) across the US with broad outreach to pain populations. EPPIC-Net investigators bring broad pain clinical and
  • research expertise
  • In the first 2 years EPPIC-net has been open to applications, 3 asset trials have been funded; one trial is now open to enrollment. EPPICNet is also developing an innovative master platform protocol for
  • therapeutics targeted to painful diabetic peripheral neuropathy
  • EPPIC-Net accepts and reviews applications from academic and industry sponsors worldwide, at any time on a rolling basis
  • 16:40 Chair's Closing Remarks and Close of Day One

    Richard Malamut

    Richard Malamut, Chief Medical Officer, MedinCell,Inc
    View Bio

    8:30 Registration and Coffee

    9:00 Chair's Opening Remarks

    Richard Malamut

    Richard Malamut, Chief Medical Officer, MedinCell,Inc
    View Bio

    9:10 Personalized Analgesics® research: a novel network biology approach to transform pain R&D

    Mark J. Field

    Mark J. Field, CEO & Founder, EptivA Therapeutics

  • Chronic pain is a huge burden to patients and society as a whole with a lack of safe and effective analgesic treatments
  • Innovation in the pain area is extremely low with few new medicines reaching patients due to exceptionally high attrition rates in R&D.
  • New transformative approaches for pain drug development are required to improve the probability of R&D success and encourage increased investments into the area
  • This presentation will describe a novel Personalized Analgesics® network biology approach to link research targets to disease, based on our development of the Pain Landscape® the Pain diseasome®
  • Creating R&D methods that link the mechanistic research target to the most appropriate disease can develop more precision-analgesics de-risking R&D and helping create improved solutions for patients
  • 9:50 Canine Models of Chronic Pain

    Christina de Rivera

    Christina de Rivera, CSO - companion animal department, Intervivo Solutions
    View Bio

  • Dogs naturally develop chronic pain conditions similar to humans.
  • Due to the similarities, dogs can be used as translational models for evaluating novel therapeutics.
  • New data evaluating biomarker changes in canine models to establish secondary therapeutic endpoints will be discussed.
     
  • 10:30 Morning Coffee

    11:00 Proof of target engagement of new analgesics in early phase clinical drug studies in healthy volunteers

    Geert Jan Groeneveld

    Geert Jan Groeneveld, CSO/CMO, Centre for Human Drug Research

  • Demonstrating target engagement early in in the clinical phase of drug development is essential and can assist in streamlining the process of drug development by selecting the most promising candidates early and stopping work on the less promising ones.
  • Demonstrating target engagement in the development of new analgesics can be done using evoked pain tests in healthy subjects, by adding patients with pain to the early clinical pharmacology studies, or using measurement methods that mechanistically demonstrate the intended pharmacology
  • Examples of each three models will be given. A special role will be played by CHDR’s pain test battery called the PainCart®.
  • Results of recent studies where PainCart® was combined with challenges leading to lowered pain thresholds in healthy subjects than can be considered forms of centrally induced hyperalgesia will be presented.
  • 11:40 The next Generation of Opioids in development.

    Lynn Kirkpatrick

    Lynn Kirkpatrick, President and CEO, Ensysce Biosciences Inc.

  • Chronic pain – it’s not going away.
  • Abuse protection vs deterrence – what is the difference?
  • 2 new classes of safer opioids – “tAAP and MPAR” – what is behind the acronyms?
  • Clinical data on PF614 – a tAAP opioid from Ensysce Biosciences.
  • 12:20 Networking Lunch

    13:20 Novel Plant-Inspired Pain Therapeutics

    Andrea Small-Howard

    Andrea Small-Howard, President & Chief Science Officer, GB Sciences, Inc.

  • Plant-based remedies for pain have been a part of Traditional Medicine for thousands of years
  • To reduce our reliance on opioids for pain, plant-based remedies are being adapted for the prescription drug market as ‘plant-inspired’ drugs
  • Cannabis-based remedies for pain are emerging as a viable option with improved safety profiles
     
  • 14:00 Long-term consequences of silencing pain pathways with novel Botulinum constructs

    Maria  Maiaru

    Maria Maiaru, Lecturer in Pharmacology, University of Reading
    View Bio

  • There is an urgent need for more effective and safer treatment for chronic pain.
  • A single intrathecal injection of botulinum toxin conjugate produces a long-lasting pain relief in a mouse model of neuropathic pain without toxic side effects.
  • This strategy might be a safer and effective approach for relieving chronic pain while avoiding the adverse events associated with repeated chronic drug administration.
  • 14:40 Afternoon Tea

    15:10 First-in-class HCn1 selective inhibitors for the management of neuropathic pain

    Steve Fox

    Steve Fox, Chairman, Akelos Inc
    View Bio

  • An introduction to Chemotherapy Induced Peripheral Neuropathy (CIPN)
  • The current treatments for these patients and their challenges
  • Target engagement HCN1 in human sensory neurons
  • Financing optimisation into first-in-human clinical trials
  • 15:50 Using opioids to treat opioid use disorder

    Joshua Cohen

    Joshua Cohen, Chief Medical Officer, Braeburn

  • The opioid epidemic: A worsening public health crisis
  • The science behind opioid use disorder
  • Current treatment paradigms and patient unmet needs
  • Medications for opioid use disorder (MOUDs) – scientific rationale and clinical data
  • 16:30 Opioids and Cannabinoids, traditional or novel treatments?

  • The benefits and dangers of using opioids for the treatment of chronic pain
  • The use of cannabinoids and how this is different to opioids
  • Benefits and challenges of both opioids and cannabinoids
  • The future of the use of these compounds and what it means for chronic pain
  • Joshua Cohen

    Joshua Cohen, Chief Medical Officer, Braeburn

    Andrea Small-Howard

    Andrea Small-Howard, President & Chief Science Officer, GB Sciences, Inc.

    Lynn Kirkpatrick

    Lynn Kirkpatrick, President and CEO, Ensysce Biosciences Inc.

    Arun Bhaskar

    Arun Bhaskar, President, The British Pain Society
    View Bio

    17:10 Chair's Closing Remarks and Close of Day Two

    Richard Malamut

    Richard Malamut, Chief Medical Officer, MedinCell,Inc
    View Bio

    +

    FEATURED SPEAKERS

    Andrea Small-Howard

    Andrea Small-Howard

    President & Chief Science Officer, GB Sciences, Inc.
    Arun Bhaskar

    Arun Bhaskar

    President, The British Pain Society
    Barbara Karp

    Barbara Karp

    Program Director, EPPIC-Net, National Institutes Of Health
    Candler Paige

    Candler Paige

    Chief Executive Officer, Doloromics
    Christina de Rivera

    Christina de Rivera

    CSO - companion animal department, Intervivo Solutions
    Domenico Merante

    Domenico Merante

    Clinical Development Lead of Nephrology and Orphan Diseases, Vifor Pharma Ltd
    Geert Jan Groeneveld

    Geert Jan Groeneveld

    CSO/CMO, Centre for Human Drug Research
    Ilona Steigerwald

    Ilona Steigerwald

    Experienced Senior Executive and Chief Medical Officer, SVP,
    Joshua Cohen

    Joshua Cohen

    Chief Medical Officer, Braeburn
    Lynn Kirkpatrick

    Lynn Kirkpatrick

    President and CEO, Ensysce Biosciences Inc.
    Maria  Maiaru

    Maria Maiaru

    Lecturer in Pharmacology, University of Reading
    Mark J. Field

    Mark J. Field

    CEO & Founder, EptivA Therapeutics
    Michael J. Seminerio

    Michael J. Seminerio

    Senior Global Scientific/Medical Lead Migraine Neuroscience, AbbVie Pharmaceuticals
    Neil Singla

    Neil Singla

    Chief Executive Officer, Lotus Clinical Research, LLC
    Richard Malamut

    Richard Malamut

    Chief Medical Officer, MedinCell,Inc
    Steve Fox

    Steve Fox

    Chairman, Akelos Inc
    Todd Krueger

    Todd Krueger

    President and CEO, AOBiome

    Andrea Small-Howard

    President & Chief Science Officer, GB Sciences, Inc.
    Andrea Small-Howard

    Arun Bhaskar

    President, The British Pain Society
    Arun Bhaskar

    Dr Bhaskar is the current President of the British Pain Society and has served two terms as an elected member of the Council of the British Pain Society. Dr Bhaskar is also the present Chairman of the UK Section, World Institute of Pain. Dr Bhaskar is also a Co-opted Member of the Board of The Faculty of Pain Medicine, Royal College of Anaesthetists. He is also the Hon. Secretary of the Neuromodulation Society of UK and Ireland. Dr Bhaskar advises NICE on interventional procedures, cancer pain and was a co-opted member of the GDG for Care of the Dying. Dr Bhaskar is currently the Co-chair of the Committee for the Cancer Pain Management Guidelines; he is also the Co-chair of the Neuromodulation Guidelines Committee. He also represents as Councillor for the UK at the European Pain Federation and is a member of the European Pain Federation Task Force on Cancer Pain Management. Dr Bhaskar was the Co-chair for the OPEN Consensus group for Opioid Analgesic Dependency and the recommendations from specialists from Pain Medicine and Addiction Medicine. Dr Bhaskar has also represented the Faculty of Pain Medicine in the Palliative Medicine SAC, Royal College of Physicians.
    Dr Bhaskar is the Head of Service at the Pain Management Centre, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London and has special interests in complex pain, including cancer pain, neuropathic pain, visceral & pelvic pain, pain interventional procedures and neuromodulation. He has also a specific interest in opioid management in complicated cancer pain, as well as opioid dependence and its management in the pain patient population. Dr Bhaskar has been involved with several clinical trials in cancer pain, and neuropathic pain in cancer including chemotherapy-induced neuropathy. He has been involved in developing novel techniques for interventional treatment of pain including intractable cancer pain. Dr Bhaskar is on the faculty of many courses, including the European Pain School and is an examiner for the European Diploma in Pain Medicine and also the FIPP examination for the World Institute of Pain.

     

    Barbara Karp

    Program Director, EPPIC-Net, National Institutes Of Health
    Barbara Karp

    Candler Paige

    Chief Executive Officer, Doloromics
    Candler Paige

    Christina de Rivera

    CSO - companion animal department, Intervivo Solutions
    Christina de Rivera

    As Chief Scientific Officer – companion animal department, of InterVivo Solutions, Christina is focused on optimizing the translational value of InterVivo's services to facilitate the development and approval of novel drugs. Christina is involved in projects utilizing, characterizing, and developing the aged dog as a natural model of age-related human diseases and is a strong proponent for the use of validated natural and/or translational animal models in drug discovery. Her scientific background includes graduate training in behavioral pharmacology at the University of Toronto and an MSc in Speech Language Pathology, more than 20 refereed publications and several invited presentations.

    Domenico Merante

    Clinical Development Lead of Nephrology and Orphan Diseases, Vifor Pharma Ltd
    Domenico Merante

    Dr Domenico Merante graduated in medicine in 1988 and became specialist of endocrinology and diabetes in 1993, both degrees were achieved at University of Pisa/Italy. Dr Merante has spent 27+ years in the pharmaceutical industry in Italy, UK, US and Switzerland dedicating his career to the clinical development of medicines targeting type 1 and 2 diabetes, diabetic complications (macular edema, painful diabetic neuropathy), severe hypertension, infectious diseases, iron deficiency anemia and thrombocytopenia in chronic liver diseases, lately fibromyalgia and ANCA-Associated Vasculitis MPA and GPA. Dr Merante is currently Clinical Research Lead of Nephrology and Orphan Diseases at Vifor Pharma Headquarter in Zurich, Switzerland. He previously worked at Sosei Heptares as VP of Clinical Development and before at Shionogi UK as Head of Clinical Science in 2017 and 2018. Between 2007 and 2016 Dr Merante was Senior Director of Clinical Development at Daiichi Sankyo Development UK heading the European Frontiers/Opportunity Department. Dr Merante covered clinical positions at Laboratori Guidotti in Italy, Novo Nordisk in the UK and Eli Lilly and GSK in Italy. To date Dr Merante has produced 111 publications amongst full papers, abstracts or posters in reputed journals as either main or co-author and he has given numerous presentations during National and International scientific conferences.

     

    Geert Jan Groeneveld

    CSO/CMO, Centre for Human Drug Research
    Geert Jan Groeneveld

    Ilona Steigerwald

    Experienced Senior Executive and Chief Medical Officer, SVP,
    Ilona Steigerwald

    Ilona Steigerwald, MD is a highly experienced Senior Executive with a an over 25-year career in the Pharmaceutical Industry largely dedicated to the development and characterization of novel analgesics (opioids and non-opioids) for the treatment of acute and chronic pain. She has an international professional background in both, Midsize to Big Pharma and small biotech companies. In her immediate past role as Chief Medical Officer (SVP) of Neumentum, Inc. she was responsible for the development of a pipeline of non-opioid analgesics for acute and chronic pain. In her previous over 20 years at Grünenthal GmbH she held various senior positions of increasing responsibility in Research and Development as well as Medical Affairs (VP). As Business Lead Late R&D (SVP), she was strategically responsible for the company´s international late Development pipeline (post PoC). Ilona has a broad experience with clinical trials in acute and chronic pain as well as certain rare diseases. She has extensively published in peer-reviewed journals, and at numerous international congresses (abstracts/posters) with a focus on various pain indications and analgesics.

    Joshua Cohen

    Chief Medical Officer, Braeburn
    Joshua Cohen

    Lynn Kirkpatrick

    President and CEO, Ensysce Biosciences Inc.
    Lynn Kirkpatrick

    Maria Maiaru

    Lecturer in Pharmacology, University of Reading
    Maria  Maiaru

    Dr. Maria Maiarú is a Lecturer at the University of Reading, UK. Her research focuses on the understanding of the molecular biology of pain states for the development of more effective treatments.
    Currently, research in her lab is organised around 2 themes: 1. the role of autophagic mechanisms in the development of chronic pain conditions and 2. the use of Botulinum-based constructs to relief chronic pain states and associated comorbidities. Using behavioural and molecular approaches and together with her collaborators Prof Stephen Hunt (Reading University) and Professor Bazbek Davletov (Sheffield University), Dr Maiarú has leveraged the neurotoxic properties of botulinum toxin to specifically silence key pain-processing neurons in the spinal cords of mice and the research was published in Science Translational Medicine.

    Dr. Maiarú studied Pharmacy at the “University of Magna Graecia”, Catanzaro, in Italy. She then started a PhD in the department of Pharmacology at the University of Calabria, Italy. Dr Maiarú joined UCL where she carried out the last year of her PhD under the supervision of Prof. Stephen Hunt and Dr Sandrine Géranton.

    Her involvement in neuroscience research has been recognised internationally by peers. Dr Maiarú was awarded the UCL Early Career Neuroscience Prize in 2016 and the Trainee Professional Development Award from Society of Neuroscience (SfN) in 2016. In 2017 she was invited as expert at the “Talent Innovation Pain” meeting and she presented her research on Botulinum at the Toxin meeting in Copenhagen (2019). Dr Maiarú is Co-Investigator of a grant recently awarded from the Medical Research Council (MRC) and she was personally awarded a ROSETREES TRUST Grant to investigate the role of Autophagy in the development and maintenance of Chemotherapy-induced neuropathy.

     

    Mark J. Field

    CEO & Founder, EptivA Therapeutics
    Mark J. Field

    Michael J. Seminerio

    Senior Global Scientific/Medical Lead Migraine Neuroscience, AbbVie Pharmaceuticals
    Michael J. Seminerio

    Neil Singla

    Chief Executive Officer, Lotus Clinical Research, LLC
    Neil Singla

    Dr. Neil Singla, a board-certified anesthesiologist, is the founder and Chief Scientific Officer of Lotus Clinical Research, a research site network, full-service CRO and scientific/ regulatory consulting firm specializing in analgesic therapies. Since its inception in 2001, Dr. Singla has served in several roles within the organization including: Research Coordinator, Sub-Investigator, Principal Investigator, Coordinating Investigator, and Chief Executive Officer. In 2021, Lotus merged with Evolution Research Group, expanding the combined organization’s specialized research site network to over 15 centers.

    Dr. Singla has had the opportunity to interact frequently with the FDA’s Analgesics Division on behalf of clients and to play a significant role in guiding development strategies for dozens of therapeutic agents. In the company’s 21-year history, Dr. Singla and Lotus Clinical Research have played a significant role in bringing several molecules to market.
     

    Richard Malamut

    Chief Medical Officer, MedinCell,Inc
    Richard Malamut

    Dr. Malamut is currently Chief Medical Officer at MedinCell Inc. He was most recently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals and has also served as Chief Medical Officer for Braeburn Pharmaceuticals, Inc. where he was responsible for the company’s medical affairs, non-clinical and clinical development, clinical operations, research and development quality assurance, and pharmacovigilance functions. Prior to that, Dr. Malamut had similar responsibilities as Chief Medical Officer at Avanir Pharmaceuticals and was Senior Vice President of Global Clinical Development at Teva Pharmaceutical Industries Ltd where he was responsible for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities. His experience also includes roles of increasing responsibility focusing on early clinical development and translational medicine in Neurology, Psychiatry and Analgesia at Bristol-Myers Squibb and AstraZeneca.

    Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in Neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease.
     

    Steve Fox

    Chairman, Akelos Inc
    Steve Fox

    Dr. Steven Fox is the founder and chairman of Akelos Inc., a biopharmaceutical company tackling the opioid crisis. A Scarsdale native, Steven attended Scarsdale high school and later obtained his B.A. from the University of Rochester and his DDS from NYU. An icon in the dental profession, Steven was the founder and CEO of Enamelon Inc. (sold to Dwight and Church) and has been serving patients for over 40 years. With Akelos, Steven and his team are dedicated to changing medical care and stopping the opioid epidemic.

    Todd Krueger

    President and CEO, AOBiome
    Todd Krueger

    Todd Krueger is the Chief Executive Officer, President and a Director of our Company. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Northwestern University, United States, with a Bachelor of Economics degree with Highest Distinction, and earned his Master of Business Administration degree from the Kellogg School of Management, Northwestern University, United States.

    Sponsors and Exhibitors

    Sponsors

    Official Media Partner

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SAE Media Group. SAE Media Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Preliminary Attendees List

    Download

    Pain Therapeutics Brochure 2022

    Download

    Speaker Interview - Domenico Merante, Vifor Pharma Ltd

    Download

    Speaker Interview - Lynn Kirkpatrick, Ensysce Biosciences Inc.

    Download

    Speaker Interview - Todd Krueger, AOBiome

    Download

    Speaker Interview - Andrea Small - Howard, GB Sciences, Inc.

    Download

    Speaker Interview - Michael Seminerio, Teva Pharmaceuticals

    Download

    Conference Chair Letter

    Download

    Workshop Agenda

    Download

    Past Attendees

    Download

    Past Presentation - Tina Doshi, John Hopkins University

    Download

    Past Presentation - Randall Kaye, Neurana Pharmaceuticals

    Download

    Past Presentation - Orna Green, Clexio Biosciences

    Download

    Past Presentation - Neil Singla, Lotus Clinical Research LLC

    Download

    Past Presentation - Max Mirza, Sygnature Discovery

    Download

    Past Presentation - David Thomas, NIH

    Download

    Sponsors and Exhibitors


    InterVivo Solutions

    Sponsors and Exhibitors
    https://www.transpharmation.co.uk/

    Recently merged, Transpharmation and InterVivo Solutions form the largest boutique neuroscience-specialised CRO, with 120 staff, a delivery footprint extending across North America, UK and Europe, and increased capacity and opportunities for greater scientific collaboration globally. Building on the international reputation and CNS drug discovery expertise of the founders, we are recognised by drug developers worldwide for researching and delivering life-changing medicines. Clients benefit from decades of experience in cross-species and cross-therapeutic area translational biology throughout multiple neuroscience preclinical services, including psychedelics, pain, EEG, cognition, epilepsy, neurodegeneration and anxiety/mood disorders, together with a biomarker platform and human tissue capabilities. Science will always remain our passion driven by a desire to make a difference.

    Sponsors


    Centre for Human Drug Research

    Sponsors
    http://www.chdr.nl/

    Since 1987, CHDR has developed into a unique research organisation specialising in early phase studies which combines knowledge and academic collaborations with operational excellence in clinical trial services. CHDR's strong track record in analgesic and pain research allows us to offer an efficient route towards proof of concept in patients.



    Lotus Clinical Research

    Sponsors
    http://www.LotusCR.com

    Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments, focused on improving the scientific accuracy of analgesic programs. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain, providing scientific leadership at every step of the development process.

    Media Partners


    ACNR

    Official Media Partner
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.

    Media Partners


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Hospital & Healthcare Management

    Supporters
    https://www.hhmglobal.com/media-pack



    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out